TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16223400

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% plus 0.5 mg/kg ketamine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% plus 0.5 mg/kg ketamine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bupivacaine 0.25%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ropivacaine 0.2%
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study: 11691535

Group type: EXPERIMENTAL
Intervention: Transcatheter closure of ASD
Number of subjects: 38
Study: 9163650

Group type: COMPARATOR
Intervention: Isotonic saline with 2 L x min(‐1) oxygen
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 10 mg morphine with 2 L x min(‐1) oxygen
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 20 mg morphine with 2 L x min(‐1) oxygen
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 10 mg morphine without oxygen (prongs fixed, no flow)
Number of subjects: 17
Study: 7832871

Group type: EXPERIMENTAL
Intervention: Programmed jogging 3 times per week for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no programmed jogging)
Number of subjects: 30
Study: 3118752

Group type: EXPERIMENTAL
Intervention: Tunnelled catheters
Number of subjects: 81

Group type: COMPARATOR
Intervention: Non-tunnelled catheters
Number of subjects: 81
Study: 1973472

Group type: EXPERIMENTAL
Intervention: Methotrexate 15 mg weekly
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 4571398

Group type: EXPERIMENTAL
Intervention: Higher dose of terbutaline (0.075 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29471460

Group type: EXPERIMENTAL
Intervention: In-person coaching
Number of subjects: 148

Group type: COMPARATOR
Intervention: Webinar coaching
Number of subjects: 148
Study: 28768263

Group type: EXPERIMENTAL
Intervention: Saline rectal washout (RW)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Glycerin suppositories (GS)
Number of subjects: 61
Study: 25900749

Group type: EXPERIMENTAL
Intervention: Dalteparin 5000 units once daily for 2 weeks
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study: 24072754

Group type: EXPERIMENTAL
Intervention: Relatives' Education And Coping Toolkit (REACT) intervention
Number of subjects: 103

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 103
Study: 20848523

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional non-biologic therapies
Number of subjects: 0
Study: 19817934

Group type: EXPERIMENTAL
Intervention: Aggressive blood pressure goals (< or =115/75 mm Hg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard blood pressure goals (< or =130/80 mm Hg)
Number of subjects: 0
Study: 17047290

Group type: EXPERIMENTAL
Intervention: Flunisolide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 14709579

Group type: EXPERIMENTAL
Intervention: 80% oxygen (FIO2 of 0.80)
Number of subjects: 165

Group type: COMPARATOR
Intervention: 35% oxygen (FIO2 of 0.35)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Patients with SSI
Number of subjects: 165
Study: 11229782

Group type: EXPERIMENTAL
Intervention: Antidepressant drugs (specific drugs not mentioned)
Number of subjects: 0
Study: 9115917

Group type: EXPERIMENTAL
Intervention: Water exposure (15 min twice daily for 2 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no water exposure)
Number of subjects: 21
Study: 7957349

Group type: EXPERIMENTAL
Intervention: Iodine-123 labelled low-density lipoprotein (123I-LDL)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Indium-111 labelled low-density lipoprotein (111In-LDL)
Number of subjects: 2
Study: 3310576

Group type: EXPERIMENTAL
Intervention: Diltiazem (mean 216 mg/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Atenolol (mean 80 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 29801496

Group type: EXPERIMENTAL
Intervention: Community Health Campaigns (CHCs)
Number of subjects: 4941

Group type: COMPARATOR
Intervention: Clinics
Number of subjects: 4941
Study: 27013248

Group type: EXPERIMENTAL
Intervention: Exercise stress echo (ESE)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Exercise electrocardiography (ExECG)
Number of subjects: 385
Study: 25929253

Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg
Number of subjects: 152

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 152
Study: 23782792

Group type: EXPERIMENTAL
Intervention: Imaging guided left ventricular lead positioning
Number of subjects: 192
Study: 22127693

Group type: EXPERIMENTAL
Intervention: golimumab 100 mg plus MTX
Number of subjects: 637

Group type: COMPARATOR
Intervention: placebo plus MTX
Number of subjects: 637
Study: 19130931

Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 0
Study: 16968350

Group type: EXPERIMENTAL
Intervention: DDMI (two-session motivational interview)
Number of subjects: 44

Group type: COMPARATOR
Intervention: SI (two-session standard psychiatric interview)
Number of subjects: 44
Study: 15458233

Group type: EXPERIMENTAL
Intervention: LIG-2 (1%w/w IDU in 5%w/w HPMC K4M gel base)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LIG-1 (1%w/w IDU in 2%w/w HPMC K4M gel base)
Number of subjects: 20

Group type: COMPARATOR
Intervention: LIG-1 and LIG-2
Number of subjects: 20

Group type: COMPARATOR
Intervention: LIG-1
Number of subjects: 20

Group type: COMPARATOR
Intervention: LIG-2
Number of subjects: 20
Study: 11275394

Group type: EXPERIMENTAL
Intervention: St. John's wort (3 tablets each containing 900 microg total hypericin, for 5 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: St. John's wort
Number of subjects: 54
Study: 9395363

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (125 mg/day)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (250 mg/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 7955817

Group type: EXPERIMENTAL
Intervention: Flumazenil (1.0 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3555585

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg plus hydrochlorothiazide 25 mg, given twice daily for 1 month
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg plus hydrochlorothiazide 25 mg, given once daily for 1 month
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg plus hydrochlorothiazide 25 mg, given once or twice daily for 2 months
Number of subjects: 10
Study: 31703750

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Training therapy
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Training plus acupuncture
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 96
Study: 28691640

Group type: EXPERIMENTAL
Intervention: Fatty fish
Number of subjects: 478

Group type: COMPARATOR
Intervention: Meat
Number of subjects: 478

Group type: COMPARATOR
Intervention: n-3 supplements
Number of subjects: 478
Study: 25081280

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 23452397

Group type: EXPERIMENTAL
Intervention: TREPP mesh repair
Number of subjects: 800

Group type: COMPARATOR
Intervention: TIPP procedure
Number of subjects: 800
Study: 21034290

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 1230

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 1230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1230
Study: 18304580

Group type: EXPERIMENTAL
Intervention: 5‐Hz rTMS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 10
Study: 16413753

Group type: EXPERIMENTAL
Intervention: High olive oil diet
Number of subjects: 21

Group type: COMPARATOR
Intervention: High carbohydrate, low olive oil diet
Number of subjects: 21
Study: 12826020

Group type: EXPERIMENTAL
Intervention: Sulphaphenazole (0.02-2 mg/min)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sulphaphenazole (6 mg/min) after L-NMMA (16 micromol/min) and ibuprofen (1200 mg, orally)
Number of subjects: 11

Group type: COMPARATOR
Intervention: L-NMMA (4 micromol/min) and ibuprofen (1200 mg, orally)
Number of subjects: 11
Study: 10883425

Group type: EXPERIMENTAL
Intervention: New positioning device for precise femoral insertion of the ACL autograft
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other positioning procedures
Number of subjects: 0
Study: 8925987

Group type: EXPERIMENTAL
Intervention: Short parenteral treatment with antibiotics (exact dosage and duration not specified)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional long course treatment with antibiotics (exact dosage and duration not specified)
Number of subjects: 63
Study: 1598444

Group type: EXPERIMENTAL
Intervention: CPAP group
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: lobar CPAP group
Number of subjects: 22

Group type: COMPARATOR
Intervention: lobar CPAP
Number of subjects: 22

Group type: COMPARATOR
Intervention: total lung CPAP ventilation
Number of subjects: 22
Study: 6693780

Group type: EXPERIMENTAL
Intervention: Encapsulated liquid preparation of 8‐MOP
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oxsoralen
Number of subjects: 12
Study: 31566209

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 109
Study: 30147307

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FP/SAL) 250/50 µg
Number of subjects: 406

Group type: COMPARATOR
Intervention: Tiotropium bromide (TIO) 18 µg
Number of subjects: 406
Study: 25821315

Group type: EXPERIMENTAL
Intervention: IFNα2a, RBV and Q‐e‐I (5 g, orally, thrice daily in divided doses)
Number of subjects: 60

Group type: COMPARATOR
Intervention: IFNα2a, RBV and placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IFNα2a, RBV and Q‐e‐I
Number of subjects: 60
Study: 24219376

Group type: COMPARATOR
Intervention: 1.5 g/day of ResistAid
Number of subjects: 75

Group type: COMPARATOR
Intervention: 4.5 g/day of ResistAid
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 75
Study: 19308728

Group type: EXPERIMENTAL
Intervention: Minimally guided peer support in addition to care as usual (CAU)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Care as usual (CAU) only
Number of subjects: 106
Study: 19767527

Group type: EXPERIMENTAL
Intervention: Oral antioxidant (AO) cocktail (vitamins C and E and alpha-lipoic acid)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study: 17534808

Group type: EXPERIMENTAL
Intervention: ThinOptX IOL implantation
Number of subjects: 25

Group type: COMPARATOR
Intervention: AcrySof IOL implantation
Number of subjects: 25
Study: 15543118

Group type: EXPERIMENTAL
Intervention: Detergent-free whitening dentifrice
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fluoride-matched comparator
Number of subjects: 20
Study: 11463595

Group type: EXPERIMENTAL
Intervention: NO inhalation at 5 ppm in supine position (SP + NO)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Prone position (PP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: NO inhalation in supine position (SP + NO) for Pu ARDS
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: NO inhalation in prone position (PP + NO) for Pu ARDS
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Prone position (PP) for Epu ARDS
Number of subjects: 15
Study: 9529407

Group type: EXPERIMENTAL
Intervention: Active ultrasound treatment (1 MHz, 1.0 W/cm2, pulsed mode 1:4, 15 minutes per session)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham ultrasound treatment
Number of subjects: 45
Study: 9143885

Group type: EXPERIMENTAL
Intervention: Botox (45.4 IU average, range 25-85 IU)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Dysport (182.1 IU average, range 100-340 IU)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Comparison of Botox and Dysport
Number of subjects: 212
Study: 2015918

Group type: EXPERIMENTAL
Intervention: MRI stage
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Clinical stage
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MRI assessment of parametrial and lymph-node involvement
Number of subjects: 11
Study: 6925101

Group type: EXPERIMENTAL
Intervention: Activity-centered health curriculum
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no new health program)
Number of subjects: 20
Study: 30914378

Group type: EXPERIMENTAL
Intervention: Intestinal metabolites associated with asthma, including polyunsaturated fatty acids.
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Exclusive breast-feeding for the first 4 months of life.
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Diet rich in meats.
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Specific intestinal bacterial taxa (Christensenellaceae) and plasma metabolites (γ-tocopherol/β-tocopherol).
Number of subjects: 361
Study: 30220610

Group type: EXPERIMENTAL
Intervention: Dexamethasone 30mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no glucocorticoid or placebo)
Number of subjects: 18
Study: 27014353

Group type: EXPERIMENTAL
Intervention: Amlodipine/Valsartan 5/160 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 0
Study: 24762683

Group type: EXPERIMENTAL
Intervention: 7-day triple regimen (rabeprazole 10 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 7 days)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: 10-day triple regimen (rabeprazole 10 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 10 days)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: 7-day quadruple regimen (rabeprazole 10 mg, bismuth 220 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 7 days)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: 10-day quadruple regimen (rabeprazole 10 mg, bismuth 220 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 10 days)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the comparison between triple and quadruple regimens)
Number of subjects: 357
Study: 22802030

Group type: EXPERIMENTAL
Intervention: Experts (photo professionals)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Inexperienced individuals
Number of subjects: 118
Study: 20142631

Group type: EXPERIMENTAL
Intervention: Adiponectin-leptin ratio
Number of subjects: 70

Group type: COMPARATOR
Intervention: HOMA, QUICKI, fasting glucose/insulin ratio, McAuley index
Number of subjects: 70
Study: 19019665

Group type: EXPERIMENTAL
Intervention: Cobra Perilaryngeal Airway
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA) Classic
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: LMA Fastrach
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: LMA ProSeal
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: laryngeal tube
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: ETT (SIMS Portex, Ltd, Hythe, Kent, UK)
Number of subjects: 180
Study: 16078953

Group type: COMPARATOR
Intervention: Typical antipsychotics
Number of subjects: 2005

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 2005

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 2005

Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 2005
Study: 11850255

Group type: EXPERIMENTAL
Intervention: Amprenavir
Number of subjects: 48

Group type: COMPARATOR
Intervention: Indinavir
Number of subjects: 48
Study: 10052877

Group type: EXPERIMENTAL
Intervention: Measured portal dose images (PDIs) for lateral fields
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Measured portal dose images (PDIs) for anterior fields
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Comparison of measured and predicted portal doses for lateral fields
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Comparison of measured and predicted portal doses for anterior fields
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Off-axis differences in measured and predicted portal doses
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Detection of gas pockets during treatment
Number of subjects: 10
Study: 7525185

Group type: EXPERIMENTAL
Intervention: Interferon (given alone, in combination with conventional chemotherapy, or as maintenance therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Myelo-ablative therapy with autologous bone marrow transplantation (with or without in vitro treatment of the marrow)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiolabelled monoclonal antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Purine analogues (e.g., fludarabine)
Number of subjects: 0
Study: 2843040

Group type: EXPERIMENTAL
Intervention: Treated tissues
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo tissues
Number of subjects: 296
Study: 29682578

Group type: EXPERIMENTAL
Intervention: Diabetes group
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 26843588

Group type: EXPERIMENTAL
Intervention: MCCGA (400 mL coffee/d for 8 weeks; 420 mg CGA)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: HCCGA (400 mL coffee/d for 8 weeks; 780 mg CGA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no coffee consumption)
Number of subjects: 75
Study: 24789057

Group type: EXPERIMENTAL
Intervention: DMAU 200 mg with food
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: DMAU 800 mg with food
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: DMAU 800 mg fasting
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 22447415

Group type: EXPERIMENTAL
Intervention: Desmopressin 10, 25, 50, or 100 µg
Number of subjects: 757

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 757
Study: 21409314

Group type: EXPERIMENTAL
Intervention: Insulin treatment (two daily injections)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Glibenclamide treatment
Number of subjects: 34
Study: 19216444

Group type: COMPARATOR
Intervention: 0.1% bupivacaine continuous drip associated to fentanyl 2 lg/mL (CP‐group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Patient Controlled Epidural Analgesia (PCEA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 16148694

Group type: COMPARATOR
Intervention: Serum-free media (SFM)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 2% fetal bovine serum (FBS)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: FGF-2 and TGF-beta1 (various concentrations)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: BMP-2 and IGF-1 (various concentrations)
Number of subjects: 6
Study: 12851623

Group type: EXPERIMENTAL
Intervention: Additional stenting
Number of subjects: 79

Group type: COMPARATOR
Intervention: No additional stenting
Number of subjects: 79
Study: 10099740

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.8g oral calcium daily)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 456
Study: 8678495

Group type: EXPERIMENTAL
Intervention: MMV (mitomycin C + methotrexate + vincristine)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: MMVM (MMV + medroxyprogesterone acetate)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: MMVP (MMV + prednisolone)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (MMV)
Number of subjects: 102
Study: 1351620

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD) with amphotericin, colistin, and tobramycin applied to the oropharynx and enterally; all patients received intravenous cefotaxime for 72 hours.
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 239
Study: 6731167

Group type: EXPERIMENTAL
Intervention: Special stroke rehabilitation ward (group A, 112 strokes)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Conventional treatment locations (group C, 116 strokes)
Number of subjects: 225
Study: 30134941

Group type: EXPERIMENTAL
Intervention: Enhanced Implementation as Usual (EIAU)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low-Intensity Coaching and Feedback (LICF)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High-Intensity Coaching and Feedback (HICF)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Enhanced Implementation as Usual (EIAU) only
Number of subjects: 90

Group type: COMPARATOR
Intervention: Low-Intensity Coaching and Feedback (LICF) only
Number of subjects: 90
Study: 30641006

Group type: EXPERIMENTAL
Intervention: Hebi Formula (HF) combined with Methotrexate (MTX)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 72
Study: 25195059

Group type: EXPERIMENTAL
Intervention: Model/simulation-based lecture
Number of subjects: 20

Group type: COMPARATOR
Intervention: Didactic lecture
Number of subjects: 20
Study: 22000824

Group type: EXPERIMENTAL
Intervention: Cemented Thompson hemiarthroplasty
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cemented Exeter Trauma Stem (ETS) hemiarthroplasty
Number of subjects: 200
Study: 20862937

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with diet adjustment and aerobic exercise
Number of subjects: 61

Group type: COMPARATOR
Intervention: Diet adjustment combined with aerobic exercise (Control)
Number of subjects: 61
Study: 17914127

Group type: EXPERIMENTAL
Intervention: multi-antioxidant supplementation
Number of subjects: 186

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 186
Study: 16059622

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 and 40 microg)
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Teriparatide (40 microg)
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 microg)
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Bisphosphonate after teriparatide
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: No follow-up treatment after teriparatide
Number of subjects: 1262